Qizhi Ma
Overview
Explore the profile of Qizhi Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shu P, Lei Y, Gao G, Li X, Qin D, Zhang B, et al.
Curr Med Chem
. 2024 Feb;
PMID: 38310398
Cancer immunotherapy has demonstrated remarkable success in the treatment of multiple advanced malignancies, especially approaches to target the immune checkpoint. Nonetheless, the limited response rate remains a barrier to broader...
2.
Ma Q, Shu P, Zhou K, Wang Y
Front Oncol
. 2023 Nov;
13:1073938.
PMID: 37916176
We present a case of a woman with non-small-cell lung cancer (NSCLC) who experienced disease progression during treatment with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) osimertinib due...
3.
Gao G, Liao W, Shu P, Ma Q, He X, Zhang B, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37591632
Backgrounds: Chimeric antigen receptor (CAR)-modified T cells (CAR-T) are limited in solid tumors due to the hostile tumor microenvironment (TME). Combination therapy could be a promising approach to overcome this...
4.
Zhang B, Hu M, Ma Q, Li K, Li X, He X, et al.
Mol Ther
. 2023 Apr;
31(7):2105-2119.
PMID: 37073129
Poor intratumoral infiltration is the major challenge for chimeric antigen receptor (CAR)-T cell therapy in solid tumors. Hypofractionated radiotherapy (HFRT) has been reported to induce immune cell infiltration and reshape...
5.
Zhao J, Liu B, Liu N, Zhang B, He X, Ma Q, et al.
Am J Cancer Res
. 2022 Dec;
12(11):4879-4891.
PMID: 36504886
Malignant pleural effusion (MPE) is associated with advanced stages of various malignant diseases, especially lung cancer, and is a poor prognostic indicator in these patients. However, the management of MPE...
6.
Ma Q, He X, Zhang B, Guo F, Ou X, Yang Q, et al.
Signal Transduct Target Ther
. 2022 Nov;
7(1):380.
PMID: 36402752
Pleural and peritoneal metastasis accompanied by malignant pleural effusion (MPE) or malignant ascites (MA) is frequent in patients with advanced solid tumors that originate from the lung, breast, gastrointestinal tract...
7.
Ma Q, Chen Y, Qin Q, Guo F, Wang Y, Li D
Precis Clin Med
. 2022 Jun;
4(3):155-167.
PMID: 35693216
Breast cancer is the most commonly diagnosed cancer type and the leading cause of cancer-related deaths among women worldwide. Previous studies have reported contradictory performance of chemokine CXC motif ligand...
8.
Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, et al.
J Oncol
. 2022 Jan;
2022:4259205.
PMID: 35087588
Tumor immunotherapy brings substantial and long-term clinical benefits that can even cure tumors. However, the accumulation of evidence suggests that immunotherapy also induces severe and complex neurologic immune-related adverse events...
9.
Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al.
Signal Transduct Target Ther
. 2021 Oct;
6(1):362.
PMID: 34620838
Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly...
10.
Ou X, Ma Q, Yin W, Ma X, He Z
Front Cell Dev Biol
. 2021 Jun;
9:674467.
PMID: 34095145
In recent years, immunotherapy has showed fantastic promise in pioneering and accelerating the field of cancer therapy and embraces unprecedented breakthroughs in clinical practice. The clustered regularly interspaced short palindromic...